{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:56:24Z","timestamp":1781254584456,"version":"3.54.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:01:32Z","timestamp":1773759692000},"page":"e752-e766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Georges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Gajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana S.","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Paner-Straseviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.03.009_bib0001","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2025.0023","article-title":"Multiple myeloma, version 1.2025. NCCN clinical practice guidelines in oncology","author":"Kumar","year":"2025","journal-title":"Natl Comprehen Cancer Net"},{"key":"10.1016\/j.clml.2026.03.009_bib0002","unstructured":"US Food and Drug Administration. FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma. Accessed: February 26, 2025."},{"key":"10.1016\/j.clml.2026.03.009_bib0003","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0004","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.clml.2026.03.009_bib0006","doi-asserted-by":"crossref","first-page":"TPS8074","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074","article-title":"MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Grosicki","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2026.03.009_bib0007","doi-asserted-by":"crossref","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","article-title":"MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Mateos","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.03.009_bib0008","doi-asserted-by":"crossref","first-page":"4757.1","DOI":"10.1182\/blood-2024-199752","volume":"144","author":"Nooka","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0009","doi-asserted-by":"crossref","first-page":"TPS8067","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8067","article-title":"MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Touzeau","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-022-00757-8","article-title":"Second- and third-line treatment strategies in multiple myeloma: a referral-center experience","volume":"12","author":"Goldman-Mazur","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.009_bib0011","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.03.009_bib0012","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/hematology.2023000444","article-title":"Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line","volume":"2023","author":"Hartley-Brown","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2026.03.009_bib0013","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.009_bib0014","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.009_bib0015","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0016","unstructured":"Prescribing Information. Sarclisa. Available at: https:\/\/www.products.sanofi.us\/Sarclisa\/sarclisa.pdf. Last updated October 2024. Accessed February 25, 2025."},{"key":"10.1016\/j.clml.2026.03.009_bib0017","unstructured":"Prescribing Information. Darzalex. Available at: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf. Last updated January 2025. Accessed February 25, 2025."},{"key":"10.1016\/j.clml.2026.03.009_bib0018","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0019","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0021","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0022","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.03.009_bib0023","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0024","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.03.009_bib0025","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","article-title":"Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies","volume":"36","author":"Bal","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.009_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1373548","article-title":"Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy","volume":"14","author":"Hughes","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0028","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0029","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0030","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1182\/blood.2024027342","article-title":"Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial","volume":"145","author":"Baertsch","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0032","series-title":"Presented at: 21st International Myeloma Society (IMS) Annual Meeting; September 25-28","article-title":"Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase 3 CARTITUDE-4 study update","author":"Mateos","year":"2024"},{"key":"10.1016\/j.clml.2026.03.009_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578717","article-title":"Neurotoxicity associated with chimeric antigen receptor T-cell therapy","volume":"407","author":"Wronski","year":"2025","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clml.2026.03.009_bib0034","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.009_bib0035","series-title":"Presented at: American Society of Hematology Annual Meeting and Exposition; December 6-9","article-title":"Cilta-cel safety enhancement: modifiable risk factors for delayed neurotoxicity and non-relapse mortality","author":"Sidana","year":"2025"},{"key":"10.1016\/j.clml.2026.03.009_bib0036","article-title":"Optimizing selection of bridging therapies prior to CAR-T therapy administration for multiple myeloma: clinical pearls from an expert roundtable","author":"Ailawadhi","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.03.009_bib0037","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.clml.2024.01.014","article-title":"Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable","volume":"24","author":"Ailawadhi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.03.009_bib0038","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jtct.2023.08.028","article-title":"Overcoming barriers to autologous stem cell transplantation in multiple myeloma: recommendations from a multidisciplinary roundtable discussion","volume":"29","author":"Bashir","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.03.009_bib0039","article-title":"Experience of autologous stem cell transplant in multiple yeloma: the patient and caregiver perspective","volume":"10","author":"Hansen","year":"2023","journal-title":"J Patient Exp"},{"key":"10.1016\/j.clml.2026.03.009_bib0040","first-page":"389","article-title":"Efficacy and safety of autologous stem cell transplantation in first-line treatment and at relapse in elderly patients with multiple myeloma","volume":"103","author":"Klein","year":"2025","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2026.03.009_bib0041","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0042","series-title":"Office of Oncologic Diseases Division of Hematologic Malignancies II","first-page":"1","author":"Telaraja","year":"2025"},{"key":"10.1016\/j.clml.2026.03.009_bib0043","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1182\/bloodadvances.2025016949","article-title":"Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials","volume":"9","author":"Mateos","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.009_bib0044","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0045","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05020236. Accessed May 9, 2025."},{"key":"10.1016\/j.clml.2026.03.009_bib0046","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05083169. Accessed May 9, 2025."},{"key":"10.1016\/j.clml.2026.03.009_bib0047","first-page":"SP88","article-title":"MajesTEC-9 data add to accolades for teclistamab in multiple myeloma","volume":"32","author":"Shaw","year":"2026","journal-title":"AJMC"},{"key":"10.1016\/j.clml.2026.03.009_bib0048","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual targeting of extramedullary myeloma with talquetamab and teclistamab","volume":"394","author":"Kumar","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0049","series-title":"Presented at: European Hematology Association (EHA) 2025 Hybrid Congress; June 12-15","article-title":"LB4001 Phase 2 study of talquetamab + teclistimab in patients with relapsed\/refractory multiple myeloma and extramedullary disease: RedirecTT-1","author":"Kumar","year":"2025"},{"key":"10.1016\/j.clml.2026.03.009_bib0050","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","article-title":"Defining and managing high-risk multiple myeloma: current concepts","volume":"18","author":"Costa","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2026.03.009_bib0051","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024. NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2026.03.009_bib0052","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.70015","article-title":"Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and\/or in main clone","volume":"207","author":"You","year":"2025","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1016\/j.clml.2026.03.009_bib0053","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2024.42.16_suppl.7504","article-title":"Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis","volume":"42","author":"Costa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0054","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.009_bib0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.009_bib0056","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0057","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.009_bib0058","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1016\/S2352-3026(24)00148-0","article-title":"Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial","volume":"11","author":"Yong","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.03.009_bib0059","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0060","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0061","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/S2152-2650(23)01864-5","article-title":"P-246 Real-world attrition rates after second-line therapy or later in patients from the flatiron database with relapsed\/refractory multiple myeloma refractory to lenalidomide","volume":"23","author":"Dhakal","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.03.009_bib0062","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2026.03.009_bib0063","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor-t cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2026.03.009_bib0064","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.009_bib0065","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0066","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.2025029773","article-title":"Sequential targeting multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy","volume":"146","author":"Dhakal","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0067","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood-2022-162733","article-title":"MonumenTAL-3: phase 3 trial of talquetamab + daratumumab \u00b1 pomalidomide versus daratumumab + pomalidomide + dexamethasone in relapsed\/refractory multiple myeloma following \u22651 prior line of therapy","volume":"140","author":"Cohen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0068","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0069","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.009_bib0070","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0071","series-title":"Presented at: 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6","article-title":"CARTITUDE-1 Final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","author":"Lin","year":"2023"},{"key":"10.1016\/j.clml.2026.03.009_bib0072","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2026.03.009_bib0073","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clml.2026.03.009_bib0074","doi-asserted-by":"crossref","first-page":"s405","DOI":"10.1016\/j.htct.2023.09.765","article-title":"Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma and prior B-cell maturation antigen\u2013directed therapies: a pooled analysis from magnetismm studies","volume":"45","author":"Nooka","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.clml.2026.03.009_bib0075","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0076","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/bloodadvances.2025015973","article-title":"Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed\/refractory multiple myeloma","volume":"9","author":"Adegbite","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.009_bib0077","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010064","article-title":"Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis","volume":"12","author":"Liang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clml.2026.03.009_bib0078","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapses or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0079","unstructured":"Prescribing information. Carvykti. Available at: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf. Updated April 2024. Accessed February 25, 2025."},{"key":"10.1016\/j.clml.2026.03.009_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-142629","article-title":"Real-world treatment patterns and outcomes of patients with functional high-risk (early relapse) multiple myeloma","volume":"136","author":"Belli","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.03.009_bib0081","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood-2024-204365","article-title":"Comparative outcomes of functional high-risk multiple myeloma patients with and without high-risk features at diagnosis: a commpass study analysis","volume":"144","author":"Shan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0082","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.03.009_bib0083","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11596-021-2373-7","article-title":"Anti-BCMA CAR-T cell therapy in relapsed or refractory multiple myeloma patients with impaired renal function","volume":"41","author":"He","year":"2021","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.clml.2026.03.009_bib0084","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.clml.2022.04.013","article-title":"Lack of renal recovery predicts poor survival in patients of multiple myeloma with renal impairment","volume":"22","author":"Sharma","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.03.009_bib0085","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0086","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s12325-020-01247-8","article-title":"Split first dose administration of intravenous daratumumab for the treatment of multiple myeloma (MM): clinical and population pharmacokinetic analyses","volume":"37","author":"Xu","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2026.03.009_bib0087","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2026.03.009_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0089","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.009_bib0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.HS9.0000936164.84357.ed","article-title":"P09 Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (Ndmm): updated analysis of the phase 3 Maia study","volume":"7","author":"Weisel","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2026.03.009_bib0091","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2021-146210","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.009_bib0092","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.03.009_bib0093","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0094","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0096","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0097","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.03.009_bib0098","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0099","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.009_bib0100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.03.009_bib0101","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/ejh.14365","article-title":"Pomalidomide, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: final survival and subgroup analyses from the OPTIMISMM trial","volume":"114","author":"Richardson","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2026.03.009_bib0102","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/10428194.2024.2322030","article-title":"An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study","volume":"65","author":"Perrot","year":"2024","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:05:56Z","timestamp":1781251556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S215226502600073X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}